{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:26:31Z","timestamp":1792293991536,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010676","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000}}],"reference-count":194,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010676.pub2","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T09:41:32Z","timestamp":1522921292000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antidepressants versus placebo for panic disorder in adults"],"prefix":"10.1002","volume":"2018","author":[{"given":"Irene","family":"Bighelli","sequence":"first","affiliation":[{"name":"Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen; Department of Psychiatry and Psychotherapy; Ismaningerstr. 22 Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasole","family":"Castellazzi","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Girlanda","sequence":"additional","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Guenzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guaiana","sequence":"additional","affiliation":[{"name":"Western University; Department of Psychiatry; Saint Thomas Elgin General Hospital 189 Elm Street St Thomas ON Canada N5R 5C4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Koesters","sequence":"additional","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Guenzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Turrini","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine\/School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 606-8501"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,5]]},"reference":[{"key":"10.1002\/14651858.CD010676.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder","volume":"155","author":"Ballenger","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0003|cit3","unstructured":"GlaxoSmithKline A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20 and 40 mg) given as a single oral dose daily, in the treatment of panic disorder GSK-Clinical Study Register (www.gskclinicalstudyregister.com) 1994"},{"issue":"19","key":"10.1002\/14651858.CD010676.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1001\/jama.283.19.2529","article-title":"Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial","volume":"283","author":"Barlow","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1176\/ajp.2007.164.2.273","article-title":"A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy","volume":"164","author":"Marcus","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD010676.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1176\/appi.ajp.158.12.1993","article-title":"Emotion-focused psychotherapy for patients with panic disorder","volume":"158","author":"Shear","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010676.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","article-title":"Metabotropic glutamate II receptor agonists in panic disorder: a double-blind clinical trial with LY354740","volume":"20","author":"Bergink","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archpsyc.1993.01820130046008","article-title":"A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder","volume":"50","author":"Black","year":"1993","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1192\/bjp.187.4.352","article-title":"Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study","volume":"187","author":"Bradwejn","year":"2005","journal-title":"The British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2000-12982","article-title":"The use of the panic and agoraphobia scale (P & A) in a controlled clinical trial","volume":"33","author":"Bandelow","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/ajp.155.5.603","article-title":"Comparison of aerobic exercise, clomipramine and placebo in the treatment of panic disorder","volume":"155","author":"Broocks","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1211\/fact.1999.00054","article-title":"Exercise may help treat panic disorder","volume":"4","author":"Broocks","year":"1999","journal-title":"Focus on Alternative and Complementary Therapies"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0447.1999.tb05384.x","article-title":"Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study","volume":"99","author":"Caillard","year":"1999","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD010676.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S0924-977X(99)80236-3","article-title":"A multicenter, double-blind comparison of nefazodone and placebo in the treatment of panic disorder","volume":"9","author":"Cassano","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD010676.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0447.1990.tb01401.x","article-title":"Drug treatment of panic disorder: early response to treatment as a predictor of final outcome","volume":"82","author":"Albus","year":"1990","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF02189978","article-title":"Consistencies and discrepancies in self- and observer-rated anxiety scales. A comparison between the self- and observer-rated Marks-Sheehan scales","volume":"240","author":"Albus","year":"1990","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0017|cit17","first-page":"145","article-title":"Panic disorder: a five-year follow-up study in 52 patients","volume":"11","author":"Andersch","year":"1997","journal-title":"European Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD010676.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.eurpsy.2003.03.007","article-title":"A 15-year follow-up study of patients with panic disorder","volume":"18","author":"Andersch","year":"2003","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0447.1991.tb03097.x","article-title":"Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study","volume":"365","author":"Andersch","year":"1991","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0020|cit20","first-page":"1","article-title":"Pharmacologic treatment of panic disorders: comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study","volume":"14","author":"Berlanga","year":"1991","journal-title":"Salud Mental"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02190758","article-title":"Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross-National Collaborative Panic Study","volume":"240","author":"Buller","year":"1991","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0924-977X(94)90314-X","article-title":"Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo","volume":"4","author":"Cassano","year":"1994","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.160.2.191","article-title":"Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine and placebo","volume":"160","author":"Cross National Collaborative Panic Study","year":"1992","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010676.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0022-3956(93)90023-U","article-title":"Maintenance drug therapy of panic disorder","volume":"27","author":"Curtis","year":"1993","journal-title":"Journal of Psychiatry Research"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0010-440X(91)90003-U","article-title":"The sequence of improvement of the symptoms encountered in patients with panic disorder","volume":"32","author":"Deltito","year":"1991","journal-title":"Comprehensive Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0026|cit26","first-page":"121","article-title":"Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment","volume":"52","author":"Deltito","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1521\/pedi.1988.2.4.303","article-title":"Personality disorders in panic patients: response to termination of antipanic medication","volume":"2","author":"Green","year":"1988","journal-title":"Journal of Personality Disorders"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1192\/bjp.167.4.487","article-title":"Long-term follow-up after a drug trial for panic disorder","volume":"167","author":"Katschnig","year":"1995","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010676.pub2-BIB0030|cit29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0022-3956(90)90033-M","article-title":"Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia","volume":"24","author":"Klerman","year":"1990","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0029|cit30","first-page":"59","article-title":"The design and conduct of the Upjohn Cross-National Collaborative Panic Study","volume":"22","author":"Klerman","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"17","key":"10.1002\/14651858.CD010676.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/sim.4780141707","article-title":"A multiple imputation strategy for clinical trials with truncation of patient data","volume":"14","author":"Lavori","year":"1995","journal-title":"Statistics In Medicine"},{"issue":"1-2","key":"10.1002\/14651858.CD010676.pub2-BIB0032|cit32","first-page":"59","article-title":"Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia","volume":"36","author":"Le\u00f3n","year":"1990","journal-title":"Acta Psiquiatrica y Psicologica de America Latina"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02189979","article-title":"Self- and observer assessment in anxiolytic drug trials: a comparison of their validity","volume":"240","author":"Maier","year":"1990","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02219714","article-title":"Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?","volume":"241","author":"Maier","year":"1991","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD010676.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3928\/0048-5713-19910601-11","article-title":"Agoraphobia in panic disorder: an indicator of the severity of panic disorder or a distinct diagnostic entity?","volume":"21","author":"Maier","year":"1991","journal-title":"Psychiatric Annals"},{"issue":"6","key":"10.1002\/14651858.CD010676.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0010-440X(91)90035-B","article-title":"The sequence of improvement of the symptoms encountered in patients with panic disorder","volume":"32","author":"Rifkin","year":"1991","journal-title":"Comprehensive Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0447.1991.tb03099.x","article-title":"Characteristics of panic disorder patients responding to placebo","volume":"365","author":"Rosenberg","year":"1991","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0447.1991.tb03101.x","article-title":"Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response","volume":"365","author":"Rosenberg","year":"1991","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0887-6185(02)00183-4","article-title":"The long-term course of panic disorder-an 11 year follow-up","volume":"17","author":"Swoboda","year":"2003","journal-title":"Journal of Anxiety Disorders"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02245749","article-title":"Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin","volume":"102","author":"Boer","year":"1990","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0041|cit41","first-page":"119","article-title":"Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder","volume":"25","author":"Westenberg","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/026988119300700402","article-title":"Clomipramine, a better reference drug for panic\/agoraphobia. I. Effectiveness comparison with imipramine","volume":"7","author":"Gentil","year":"1993","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/026988119300700403","article-title":"Clomipramine, a better reference drug for panic\/agoraphobia. II. Psychomotor and cognitive effects","volume":"7","author":"Marcourakis","year":"1993","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/026988119300700402","article-title":"Clomipramine, a better reference drug for panic\/agoraphobia. I. Effectiveness comparison with imipramine","volume":"7","author":"Gentil","year":"1993","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/026988119300700403","article-title":"Clomipramine, a better reference drug for panic\/agoraphobia. II. Psychomotor and cognitive effects","volume":"7","author":"Marcourakis","year":"1993","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0046|cit46","unstructured":"GlaxoSmithKline A double-blind, multicentered, flexible-dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder GSK Clinical Study Register (www.gsk-clinicalstudyregister.com)"},{"issue":"5","key":"10.1002\/14651858.CD010676.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00004714-199310000-00004","article-title":"Effect of fluvoxamine on panic disorder","volume":"13","author":"Hoehn-Saric","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/070674379504000406","article-title":"Clomipramine treatment and behaviour therapy with agoraphobic women","volume":"40","author":"Johnston","year":"1995","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0049|cit49","unstructured":"Bradwejn J Koszycki D Segal ZV Efficacy of self-administered cognitive behavior therapy and sertraline in panic disorder 156th Annual Meeting of the American Psychiatric Association San Francisco CA"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1017\/S0033291710000930","article-title":"A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder","volume":"41","author":"Koszycki","year":"2011","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4088\/JCP.v60n1205","article-title":"Paroxetine, clomipramine and cognitive therapy in the treatment of panic disorder","volume":"60","author":"Bakker","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0052|cit52","unstructured":"GlaxoSmithKline A double-blind placebo-controlled comparative study of paroxetine and clomipramine in the treatment of panic disorder GSK-ClinicalStudy Register (www.gsk-clinicalstudyregister.com)"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0054|cit54","unstructured":"Spinhoven P Van Balkom AJLM Paroxetine, clomipramine and cognitive therapy in the treatment of panic disorder American Psychiatric Association Annual Meeting Toronto, Ontario, Canada 1998"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4088\/JCP.08m04238","article-title":"A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder","volume":"70","author":"Liebowitz","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/bjp.173.1.54","article-title":"Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation","volume":"173","author":"Londborg","year":"1998","journal-title":"The British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0057|cit57","first-page":"183","article-title":"Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder","volume":"29","author":"Lydiard","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00004714-199404000-00004","article-title":"Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm","volume":"14","author":"Groot","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archpsyc.1989.01810020029006","article-title":"Imipramine dose-response relationship in panic disorder with agoraphobia","volume":"46","author":"Mavissakalian","year":"1989","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0060|cit60","unstructured":"Lydiard RB Pollack MH Judge R Michelson D Tamura R Fluoxetine in panic disorder: a placebo-controlled study 10th European College of Neuropsychopharmacology Congress, 13th-17th September 1997 Vienna, Austria 1997"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial","volume":"179","author":"Michelson","year":"2001","journal-title":"The British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0062|cit62","first-page":"135","article-title":"A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia","volume":"32","author":"Bakish","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/(SICI)1522-7154(1996)2:4<192::AID-ANXI6>3.0.CO;2-Q","article-title":"Comparison of fluvoxamine, imipramine and placebo in the treatment of outpatients with panic disorder","volume":"2","author":"Nair","year":"1996","journal-title":"Anxiety"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010676.pub2-BIB0064|cit64","first-page":"60","article-title":"Serotoninergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone","volume":"22","author":"Pohl","year":"1989","journal-title":"Psychopathology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0065|cit65","unstructured":"Baumel B Bielski R Carman J Goodman W Hegel M Houck C Double-blind comparison of sertraline and placebo in patients with panic disorder Poster Presentations P-1o-14"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/ajp.155.9.1189","article-title":"Sertraline in the treatment of panic disorder: a double-blind multicenter study","volume":"155","author":"Pohl","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial","volume":"55","author":"Pollack","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0068|cit68","unstructured":"Wolkow R Apter J Clayton A Coryell W Cunningham L McEntee W Double-blind, flexible dose study of sertraline and placebo in patients with panic disorder Poster Presentations P-10-17"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0069|cit69","unstructured":"Pollack M Whitaker T Mangano R Gao B A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder ACNP 2004 Annual Meeting S201 S202"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-007-0821-0","article-title":"A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder","volume":"194","author":"Pollack","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of venlafaxine extended-release, paroxetine and placebo in the treatment of panic disorder","volume":"24","author":"Pollack","year":"2007","journal-title":"Depression and Anxiety"},{"issue":"6 Suppl 2","key":"10.1002\/14651858.CD010676.pub2-BIB0073|cit72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199812001-00004","article-title":"Panic disorder: long-term pharmacotherapy and discontinuation","volume":"18","author":"Rickels","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0072|cit73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archpsyc.1993.01820130067010","article-title":"Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper","volume":"50","author":"Rickels","year":"1993","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1993.01820130053009","article-title":"Maintenance drug treatment of panic disorder I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine","volume":"50","author":"Schweizer","year":"1993","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0075|cit75","first-page":"150","article-title":"Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care","volume":"47","author":"Sharp","year":"1997","journal-title":"British Journal of General Practice"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0887-6185(96)00008-4","article-title":"Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia","volume":"10","author":"Sharp","year":"1996","journal-title":"Journal of Anxiety Disorders"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199002000-00002","article-title":"Buspirone effective for panic disorder?","volume":"10","author":"Sheehan","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0078|cit78","unstructured":"GlaxoSmithKline A double-blind, placebo-controlled, flexible-dosing trial to evaluate the efficacy of controlled-release paroxetine in the treatment of panic disorder GSK-Clinical Study Register (www.gsk-clinicalstudyregister.com) 1997"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0079|cit79","unstructured":"GlaxoSmithKline A double-blind, placebo-controlled, flexible-dosing trial to evaluate the efficacy of controlled-released paroxetine in the treatment of panic disorder GSK-Clinical Study Register (www.gsk-clinicalstudyregister.com) 1997"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0080|cit80","unstructured":"GlaxoSmithKline A double-blind, placebo-controlled, flexible-dosing trial to evaluate the efficacy of modified-release paroxetine in the treatment of panic disorder GSK-Clinical Study Register (www.gsk-clinicalstudyregister.com) 1997"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.v66n0105","article-title":"Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder","volume":"66","author":"Sheehan","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2190\/KQEJ-MQJR-VK3D-F3HV","article-title":"Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine and placebo","volume":"29","author":"Sheikh","year":"2000","journal-title":"International Journal of Psychiatry in Medicine"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-2007-984398","article-title":"Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo","volume":"40","author":"Bandelow","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-2007-984398","article-title":"Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo","volume":"40","author":"Bandelow","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ajp.147.4.507","article-title":"Surreptitious drug use by patients in a panic disorder study","volume":"147","author":"Clark","year":"1990","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1037\/0022-006X.59.1.184","article-title":"How \"blind\" are double-blind studies?","volume":"59","author":"Margraf","year":"1991","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00004714-199004000-00006","article-title":"Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double blind, placebo-controlled trial","volume":"10","author":"Taylor","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0090|cit90","first-page":"639","article-title":"Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor for panic disorder: a double-blind, placebo-controlled trial","volume":"19","author":"Tsutsui","year":"1997","journal-title":"Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0091|cit91","first-page":"S271","article-title":"Clinical evaluation of paroxetine Hcl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder: late phase II double-blind, parallel group study","volume":"28","author":"Tsutsui","year":"2000","journal-title":"Japanese Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0092|cit92","first-page":"S295","article-title":"Clinical evaluation of paroxetine Hcl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder: phase III double-blind, parallel group study","volume":"28","author":"Tsutsui","year":"2000","journal-title":"Japanese Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0165-0327(89)90009-8","article-title":"Response of panic disorder to fixed doses of alprazolam or imipramine","volume":"17","author":"Uhlenhuth","year":"1989","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/BF02244898","article-title":"MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine","volume":"112","author":"Vliet","year":"1993","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4088\/JCP.v63n0107","article-title":"Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well tolerated treatment for panic disorder","volume":"63","author":"Versiani","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0096|cit96","first-page":"24","article-title":"Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial","volume":"25","author":"Leinonen","year":"2000","journal-title":"Journal of Psychiatry & Neuroscience"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v59n1006","article-title":"A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder","volume":"59","author":"Lepola","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0924-977X(99)80150-3","article-title":"Weight monitoring during two long-term trials of citalopram","volume":"9 Suppl 5","author":"Wade","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1192\/bjp.170.6.549","article-title":"The effect of citalopram in panic disorder","volume":"170","author":"Wade","year":"1997","journal-title":"The British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/070674379303800106","article-title":"Changes in appetite and weight during the pharmacological treatment of patients with panic disorder","volume":"38","author":"Balon","year":"1993","journal-title":"Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000099842","article-title":"Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants?","volume":"76","author":"Dusseldorp","year":"2007","journal-title":"Psychotherapy & Psychosomatics"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0447.1986.tb02666.x","article-title":"Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison ofzimeldine, imipramine and placebo","volume":"73","author":"Evans","year":"1986","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1 pt B","key":"10.1002\/14651858.CD010676.pub2-BIB0104|cit103","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00002826-199202001-00182","article-title":"Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial","volume":"15","author":"Fahy","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0103|cit104","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0165-0327(92)90094-M","article-title":"The Galway Study of Panic Disorder I: clomipramine and lofepramine in DSM-III-R panic disorder: a placebo controlled trial","volume":"25","author":"Fahy","year":"1992","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0105|cit105","unstructured":"GlaxoSmithKline Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders GSK- Clinical Study Register (www.gsk-clinicalstudyregister.com) 2002"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1521\/pedi.1988.2.4.303","article-title":"Personality disorders in panic patients: response to termination of antipanic medication","volume":"2","author":"Green","year":"1988","journal-title":"Journal of Personality Disorders"},{"issue":"12","key":"10.1002\/14651858.CD010676.pub2-BIB0107|cit107","first-page":"481","article-title":"Clomipramine in the treatment of agoraphobic in patients resistant to behavioral therapy","volume":"54","author":"Hoffart","year":"1993","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD010676.pub2-BIB0108|cit108","first-page":"961","article-title":"Minnesota multiphasic personality inventory correlates of panic disorder with agoraphobia: changes with treatment","volume":"28","author":"Ito","year":"1995","journal-title":"Brazilian Journal of Medical and Biological Research"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00004850-198701000-00003","article-title":"Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo","volume":"2","author":"Kahn","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD010676.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.yic.0000171518.25963.63","article-title":"A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan","volume":"20","author":"Kamijima","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0111|cit111","first-page":"351","article-title":"The effectiveness of hypnosis for patients with panic disorder (2): its possibilities for reduction of symptom severity","volume":"70","author":"Kawashima","year":"2012","journal-title":"Journal of Tokyo medical University"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-0327(93)90074-T","article-title":"Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo","volume":"28","author":"Keller","year":"1993","journal-title":"Journal of Affective Disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010676.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0022-3956(90)90033-M","article-title":"Depression and panic anxiety: the effect of depressive comorbidity on response to drug treatment of patients with panic disorder and agoraphobia","volume":"24","author":"Klerman","year":"1990","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0114|cit114","first-page":"251","article-title":"Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial","volume":"12","author":"Modigh","year":"1992","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1192\/bjp.167.3.374","article-title":"Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study","volume":"167","author":"Oehrberg","year":"1995","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0116|cit116","unstructured":"Pfizer-Sertraline-Company-Study A placebo-controlled, double-blind, comparative study of sertraline in the treatment of subjects with panic disorder - randomized withdrawal study Pfizer-Clinical Study Register (www.clinicalstudyresults.com) 2003"},{"issue":"1 ptB","key":"10.1002\/14651858.CD010676.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00002826-199202001-00115","article-title":"Brofaromine and clomipramine in panic disorder: a double-blind study","volume":"15","author":"Saxena","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0118|cit118","unstructured":"Versiani MV Montgomery SA Stahl SM Schwartz GE 154th Annual Meeting of the American Psychiatry Association, 5-10 May 2001 New Orleans, LA 2001"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0119|cit119","first-page":"133","article-title":"The control study of mirtazapine in treating patients with panic disorder","volume":"17","author":"Yang","year":"2005","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0120|cit120","first-page":"186","article-title":"Effect of citalopram in the treatment of panic disorder","volume":"19","author":"Yang","year":"2006","journal-title":"Shandong Archives of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0121|cit121","first-page":"8","article-title":"Imipramine-induced jitteriness and decreased serum iron levels","volume":"25","author":"Yeragani","year":"1992","journal-title":"Neuropsychobiology"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0122|cit122","first-page":"12","article-title":"Venlafaxine plus cognitive behavior therapy in treatment of panic disorder","volume":"16","author":"Zhao","year":"2003","journal-title":"Shandong Archives of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010676.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/archpsyc.1983.01790020019002","article-title":"Treatment of phobias. Comparison of imipramine hydrochloride and placebo","volume":"40","author":"Zitrin","year":"1983","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0124|cit124","unstructured":"Anon Placebo-controlled study of efficacy of imipramine, diazepam, baclofen and propranolol in patients with panic disorder Obozrenie Psikhiatrii Med Psikhologii Im V M Bekhtereva 1994 43 50"},{"issue":"5","key":"10.1002\/14651858.CD010676.pub2-BIB0125|cit125","first-page":"3","article-title":"Treatment of autonomic crises (attacks of panic)","volume":"91","author":"Diukova","year":"1991","journal-title":"Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0126|cit126","first-page":"22","article-title":"Treatment of autonomic attacks (panic attacks)","volume":"26","author":"Diukova","year":"1993","journal-title":"Journal of Russian and East European Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0127|cit127","unstructured":"Mallick R Gao B Quality of life and functionality in panic disorder improve with treatment 156th Annual Meeting of the American Psychiatric Association, 17-22 May 2003 San Francisco, CA 2003"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010676.pub2-BIB0128|cit128","first-page":"223","article-title":"Short-term treatment of panic disorder with venlafaxine XR or paroxetine: a placebo-controlled trial","volume":"16","author":"Musgnung","year":"2005","journal-title":"Psychiatriki"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0129|cit129","unstructured":"Papp LA Pharmacotherapy Xth World Congress of Psychiatry, 23-28 August, 1996 Madrid, Spain 1996"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0130|cit130","unstructured":"Pfizer Study evaluating venlafaxine ER in patients with panic disorder clinicaltrials.gov\/ct2\/show\/record\/NCT00044772?term=NCT00044772&rank=1 2009"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0131|cit131","first-page":"209","article-title":"Effect of fluvoxamine in panic disorder. A double-blind placebo-controlled study","volume":"28","author":"Sandmann","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0132|cit132","unstructured":"Schneier FR Fallon BA Lin S-H Marshall RD Vermes D Sanchez-Lacay JA Pattern analysis of a clinical trial of fluoxetine in panic disorder 151st Annual Meeting of the American Psychiatry Association, 30 May-4 June 1998 Toronto, Ontario, Canada 1998"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010676.pub2-BIB0133|cit133","first-page":"S253","article-title":"Early phase II study of paroxetine Hcl, a selective serotonin reuptake inhibitor, in the treatment of panic disorder","volume":"28","author":"Tsutsui","year":"2000","journal-title":"Japanese Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD010676.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004714-200206000-00008","article-title":"Interactive model of therapeutic response in panic disorder: moclobemide, a case in point","volume":"22","author":"Uhlenhuth","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0135|cit135","unstructured":"Wolkow R A double-blind, parallel, 12-week comparison of sertraline and placebo in patients with panic disorder Xth World Congress of Psychiatry Madrid, Spain 1996"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0136|cit136","unstructured":"Kruimel J Leue C Escitalopram trial for Irritable Bowel Syndrome (IBS) patients with panic disorder clinicaltrials.gov May 2015"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness for summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0327(99)00092-0","article-title":"Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability","volume":"58","author":"Anderson","year":"2000","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/YIC.0b013e32835a5d2e","article-title":"Newer antidepressants and panic disorder: a meta-analysis","volume":"28","author":"Andrisano","year":"2013","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0141|cit141","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0142|cit142","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423905.154688","volume-title":"American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder","author":"American Psychiatric Association","year":"2009"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1600-0447.2002.02255.x","article-title":"SSRIs vs TCAs in the treatment of panic disorder: a meta-analysis","volume":"106","author":"Bakker","year":"2002","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.v67n0914","article-title":"What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?","volume":"67","author":"Bandelow","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology","volume":"19","author":"Baldwin","year":"2005","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0146|cit146","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"issue":"9","key":"10.1002\/14651858.CD010676.pub2-BIB0147|cit147","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011567.pub2","article-title":"Antidepressants and benzodiazepines for panic disorder in adults","author":"Bighelli","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s001270050098","article-title":"Prevalence of psychiatric disorder in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS)","volume":"33","author":"Bijl","year":"1998","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0149|cit149","first-page":"405","article-title":"The problem of therapeutic efficacy indices. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00002826-199310000-00002","article-title":"Neurobiological mechanisms involved in antidepressant therapies","volume":"16","author":"Briley","year":"1993","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.160.8.1432","article-title":"Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?","volume":"160","author":"Bruce","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1345\/aph.1D267","article-title":"Industry sponsorship and authorship of clinical trials over 20 years","volume":"38","author":"Buchkowsky","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"issue":"7","key":"10.1002\/14651858.CD010676.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jclinepi.2005.11.010","article-title":"Single data extraction generated more errors than double data extraction in systematic reviews","volume":"59","author":"Buscemi","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ajp.147.4.507","article-title":"Surreptitious drug use by patients in a panic disorder study","volume":"147","author":"Clark","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educational and Psychological Measurement"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0156|cit156","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0157|cit157","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; Cape Town, South Africa, 25-28 October 2000 2000"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0158|cit158","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.151.3.413","article-title":"Panic and panic disorder in the United States","volume":"151","author":"Eaton","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"317","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD010676.pub2-BIB0165|cit165","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004364.pub2","article-title":"Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia","author":"Furukawa","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD010676.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/da.20532","article-title":"Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale","volume":"26","author":"Furukawa","year":"2009","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1176\/ajp.152.10.1438","article-title":"DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis","volume":"152","author":"Goisman","year":"1995","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.ajp.157.4.493","article-title":"Neuroanatomical hypothesis of panic disorder, revised","volume":"157","author":"Gorman","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.v67n0305","article-title":"The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Grant","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD010676.pub2-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010677","article-title":"Benzodiazepines versus placebo for panic disorder in adults","author":"Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD010676.pub2-BIB0172|cit172","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012729","article-title":"Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis","author":"Guaiana","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0174|cit174","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0175|cit175","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","article-title":"The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication","volume":"63","author":"Kessler","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.bp.107.039966","article-title":"Prevalence of common mental disorders in general practice attendees across Europe","volume":"192","author":"King","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02193476","article-title":"Delineation of two drug-responsive anxiety syndromes","volume":"5","author":"Klein","year":"1964","journal-title":"Psychopharmacologia"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD010676.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.107.041186","article-title":"Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study","volume":"1993","author":"Nash","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0182|cit182","volume-title":"Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults [CG113]","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1176\/appi.ajp.158.12.1989","article-title":"An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder","volume":"158","author":"Otto","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2014 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010676.pub2-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011004.pub2","article-title":"Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis","author":"Pompoli","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/sim.2971","article-title":"Arcsine test for publication bias in meta-analyses with binary outcomes","volume":"27","author":"R\u00fccker","year":"2008","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cpr.2009.08.011","article-title":"Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis","volume":"30","author":"S\u00e1nchez-Meca","year":"2010","journal-title":"Clinical Psychology Review"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0189|cit189","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0190|cit190","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195369250.001.0001","volume-title":"Anxiety Disorders in Adults: A Clinical Guide","author":"Starcevic","year":"2009"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/7854_2009_35","article-title":"Pharmacologic treatment of panic disorder","volume":"2","author":"Stein","year":"2010","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1002\/14651858.CD010676.pub2-BIB0192|cit192","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010676.pub2-BIB0193|cit193","first-page":"13","article-title":"Antidepressants in panic disorder","volume":"14","author":"Wade","year":"1999","journal-title":"International Clinical Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD010676.pub2-BIB0194|cit194","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010676","article-title":"Antidepressants versus placebo for panic disorder in adults","author":"Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010676.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:33:16Z","timestamp":1780367596000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010676.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,5]]},"references-count":194,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010676.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,5]]}}}